Sinclair Pharma has reported H1 ##M revenues of £ 22 m ( $ 27.2 m ) , an increase of 16 % on last year 's figure of £ 20 m . The increase is attributed to strong demand for Sinclair 's aesthetic dermatology products in Brazil . Sinclair also said Silhouette Soft sales were up 20 % to £ 7.3 m , and first - sales for Silhouette InstaLift hit £ 2.3 m . Even better results are expected in the second half of the year , according to CEO Chris Smith .
Sinclair Pharma has reported H1 2017 revenues of £20.1m ($27.2m), an increase of 16% on last year's figure of £17.3m. The growth is attributed to strong demand for Sinclair's aesthetic dermatology products in Brazil. Sinclair also said Silhouette Soft sales were up 20% to £7.3m, and first-sales for Silhouette InstaLift hit £2.3m. Even better results are expected in the second half of the year, according to CEO Chris Spooner.